Stay updated with breaking news from Upper Limit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The approval was based on data from the APPLY-PNH trial and APPOINT-PNH study, which showed iptacopan was superior for hemoglobin improvement in the absence of red blood cell transfusions and in transfusion avoidance rate compared to patients who stayed on anti-C5 treatments.
After meeting with the FDA, Company to submit a supplemental New Drug Application to FDA in Q1 2024 for conversion of the existing U.S. accelerated approval of FILSPARI® in IgAN to full approval ...
Issues notices after several complaints.
Received 430 new patient start forms for FILSPARI® in the third quarter of 2023; demand and payer coverage continued to grow Net product sales of FILSPARI...
Two-year results from both PROTECT and DUPLEX pivotal Phase 3 studies demonstrate treatment with sparsentan has the potential to preserve kidney function and significantly delay time to kidney...